Women's Health: Worldwide Prescription Drug Markets - 3rd Edition

Questions: Discounts, Updates etc.

Pages: 368

Price (Single): $2,812.00

Price (Company): $5,625.00

Publication Date: 2003-05-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the prescription drug marketplace. Women’s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women.

Scope and Methodology

For this study, the worldwide prescription drug market for women’s health is discussed in total manufacturers’ revenues for the following product categories:

The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 62 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

All market data are presented at the manufacturers’ level in current U.S dollars. The base year for data was 2002. Historical data are provided for each of the years 1997 through 2002, and forecast data are provided for each of the years 2003 through 2007. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2002 base year.

 

Table of Contents


Chapter One: Executive Summary

Chapter Two: Introduction and Overview

Chapter Three: Autoimmune Diseases

 

Chapter Four: Cancer

Overview

Breast Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Vaginal Cancer

Market Size and Growth

Geographical Market Analysis

Research and Development

Competitive Market

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

 

  • Overview

    AIDS

    • Overview
    • Treatment

    Bacterial Vaginosis

    • Overview
    • Treatment

    Cervical Dysplasia

    • Overview
    • Treatment

      Chlamydia

      • Overview
      • Treatment

      Condyloma Acuminata

      • Overview
      • Treatment

      Genital Herpes

      • Overview
      • Treatment

      Gonorrhea

      • Overview
      • Treatment

      Hepatitis

      • Overview
      • Treatment

      Pelvic Inflammatory Disease

      • Overview
      • Treatment

      Syphilis

      • Overview
      • Treatment

      Toxic Shock Syndrome

      • Overview
      • Treatment

      Yeast Infections

      • Overview
      • Treatment

      Market Size and Growth

      Geographical Market Analysis

      Research and Development

      Competitive Market

    Chapter Six: Hormone-Related Disorders

     

      Overview

      Contraception

      • Overview
      • Treatment

      Endometriosis

      • Overview
      • Treatment

      Fibroids

      • Overview
      • Treatment

      Infertility

      • Overview
      • Treatment

      Menopause

      • Overview
      • Treatment

      Menstrual Disorders

      • Amenorrhea
      • Dysmenorrhea

      Sexual Dysfunction

      • Overview
      • Treatment

      Market Size and Growth

      Geographical Market Analysis

      Research and Development

      Competitive Market

    Chapter Seven: Osteoporosis

    • OverviewMarket Size and GrowthGeographical Market AnalysisResearch and DevelopmentCompetitive Market

    Chapter Eight: Urinary Bladder Disorders

     

      Overview

      Cystitis

      • Overview
      • Treatment

      Incontinence

      • Overview
      • Treatment
      • Alternative Treatments

      Interstitial Cystitis

      • Overview
      • Treatment

      Market Size and Growth

      Geographical Market Analysis

      Research and Development

      Competitive Market

    Chapter Nine: Issues and Trends

    • 2003 Budget Increases for Women’s Health Issues
    • Women’s Health Initiative
    • What Now? Guidance for the Industry
    • Perimenopausal Use of Contraceptives
    • Fosamax Patents Void in European Market
    • Insurance Coverage for Contraceptives
    • HPV Vaccine
    • Foreign Girls and Young Women and HIV
    • Oral Contraceptives in Japan
    • Ovarian Cancer Test
    • Immunotherapies in Ovarian Cancer
    • New Pap Test Screening Guidelines
    • Estrogen Labeling
    • New Uterine Fibroid Treatment
    • Inequality in Clinical Testing of Drugs
    • Testing for Predisposition to Cancer
    • Osteoporosis Drug Opportunities in Asia

    Chapter Ten: World Market Summary

    • Overview
    • Total Market Size and Forecast
    • Market Analysis

    Chapter Eleven: Competitor Profiles

    • Industry Structure and Participants
    • Akzo Nobel NV (Organon)
    • Amgen, Inc.
    • AstraZeneca PLC
    • Aventis
    • Barr Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Company, Inc.
    • Novartis International AG
    • Pfizer, Inc.
    • Pharmacia Corporation
    • Procter & Gamble Company
    • Roche
    • Schering AG
    • Serono International S.A.
    • Wyeth

    Appendix: Company Directory

    List of Exhibits

     

    • Table 1-1: The Worldwide Market for Women’s Healthcare, Revenues bySegment, 1997-2007
    • Figure 1-1: The Market for Women’s Healthcare Revenues bySegment 1997-2007
    • Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2000
    • Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2000 (Difference, in Years, between Females and Males)
    • Table 2-2: World Population Growth, by Total World Population and Selected Country or Regions and Selected Characteristics
    • Figure 2-2: World Population Growth by Sex 2000, 2002, 2010, 2020, 2025
    • Figure 2-3: United States Population Growth bySex 2000, 2002, 2010, 2020, 2025
    • Figure 2-4: Five Major European Countries* Population Growth bySex 2000, 2002, 2010, 2020, 2025
    • Figure 2-5: Japan Population Growth by Sex 2000, 2002, 2010, 2020, 2025
    • Table 2-3: World Female Population Growth by Selected Country or Regions and Selected Age Group
    • Figure 2-6: World Female Population Growth by Selected AgeGroup 2000, 2002, 2010, 2020, 2025
    • Figure 2-7: United States Female Population Growth by Selected AgeGroup 2000, 2002, 2010, 2020, 2025
    • Figure 2-8: Five Major European Countries Female Population Growth bySelected Age Group 2000, 2002, 2010, 2020, 2025
    • Figure 2-9: Japan Female Population Growth by Selected Age Group 2000, 2002, 2010, 2020, 2025
    • Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type and Geographical Distribution
    • Table 2-5: Estimated Incidence of Female Cancers and Mortality by Type and Geographical Distribution
    • Table 2-6: Estimated Female Incidence and Prevalence Gynecological andSexually Transmitted Diseases by Type and Geographical Distribution
    • Table 2-7: Gynecological and Sexually Transmitted Diseases RelatedEpidemiologic Data
    • Table 2-8: Estimated World and U.S. Female Incidence and Prevalence ofHormone-Related Disorders and Indications by Type
    • Table 2-9: Estimated World and U.S. Contraceptive Use by Method
    • Table 2-10: Estimated Female Prevalence of Osteoporosis by Type andGeographical Distribution
    • Table 2-11: Estimated Female Incidence and Prevalence of Urinary Bladder Disorders by Type and Geographical Distribution
    • Table 2-12: Estimated Female Statistics Concerning Lifestyle Patterns Contributing to Disease by Type of Behavior and Geographical Distribution
    • Table 3-1: The World Market for Autoimmune Disease Drugs for Women byType 1997-2007
    • Figure 3-1: The World Market for Autoimmune Disease Drugs for WomenRevenues by Type 1997-2007
    • Table 3-2: The World Market for Autoimmune Disease Drugs for WomenMarket Share by Type 1997-2007
    • Figure 3-2: The World Market for Autoimmune Disease Drugs for WomenShare by Type 2002 & 2007
    • Table 3-3: The World Market for Autoimmune Disease Drugs for WomenRevenues by Geographical Region 1997-2007
    • Table 3-4: The World Market for Autoimmune Disease Drugs for WomenShare by Geographical Region 1997-2007
    • Figure 3-3: The World Market for Autoimmune Disease Drugs for WomenShare by Geographic Region 2002 and 2007
    • Table 3-5: Products in Development for Selected Autoimmune Diseases 2002
    • Table 3-6: The World Market for Autoimmune Disease Drugs for WomenRevenues and Market Share by Supplier 2002
    • Figure 3-4: The World Market for Autoimmune Disease Drugs for WomenMarket Share by Leading Supplier 2002
    • Table 4-1: The World Market for Cancer Drugs for Women byType 1997-2007
    • Figure 4-1: The World Market for Cancer Drugs for Women Revenues byType 1997-2007
    • Table 4-2: The World Market for Cancer Drugs for Women Market Share byType 1997-2007
    • Figure 4-2: The World Market for Cancer Drugs for Women Share byType 2002 and 2007
    • Table 4-3: The World Market for Cancer Drugs for Women Revenues by Geographical Region 1997-2007
    • Table 4-4: The World Market for Cancer Drugs for Women Share byGeographical Region 1997-2007
    • Figure 4-3: The World Market for Cancer Drugs for Women SharePercentage 2002 and 2007
    • Table 4-5: Products in Development for Women’s Cancers
    • Table 4-6: The World Market for Cancer Drugs for Women Revenues andMarket Share by Supplier 2002
    • Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2002
    • Table 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women by Type 1997-2007
    • Figure 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Type 1997-2007
    • Table 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women, Market Share by Type 1997-2007
    • Figure 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Type 2002 and 2007
    • Table 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by GeographicalRegion 1997-2007
    • Table 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographical Region 1997-2007
    • Figure 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by GeographicRegion 2002 and 2007
    • Table 5-5: Products in Development for Women’s Gynecological Infections and Sexually Transmitted Diseases
    • Table 5-6: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues and Market Share bySupplier 2002
    • Figure 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Market Share by Leading Supplier 2002
    • Table 6-1: Selected Oral Contraceptives Available 2002
    • Table 6-2: Selected Hormone Replacement Therapies
    • Table 6-3: The World Market for Hormone-Related Disorder Drugs forWomen by Type 1997-2007
    • Figure 6-1: The World Market for Hormone-Related Disorder Drugs forWomen by Type 1997-2007
    • Table 6-4: The World Market for Hormone-Related Disorder Drugs forWomen Market Share by Type 1997-2007
    • Figure 6-2: The World Market for Hormone-related Disorder Drugs forWomen Share by Type 2002 and 2007
    • Table 6-5: The World Market for Hormone-Related Disorder Drugs forWomen Revenues by Geographical Region 1997-2007
    • Table 6-6: The World Market for Hormone-Related Disorder Drugs forWomen Share by Geographical Region 1997-2007
    • Figure 6-3: The World Market for Hormone-Related Disorder Drugs forWomen Share by Geographic Region 2002 and 2007
    • Table 6-7: Hormonal Preparations in Research and Development for Women
    • Table 6-8: The World Market for Hormone-Related Disorder Drugs forWomen Revenues and Market Share by Supplier 2002
    • Figure 6-4: The World Market for Hormone-Related Disorder Drugs forWomen Market Share by Leading Supplier 2002
    • Table 7-1: The World Market for Osteoporosis Drugs for WomenRevenues by Type 1997-2007
    • Figure 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type 1997-2007
    • Table 7-2: The World Market for Osteoporosis Drugs for Women, MarketShare by Type 1997-2007
    • Figure 7-2: The World Market for Osteoporosis Drugs for Women Share byType 2002 and 2003
    • Table 7-3: The World Market for Osteoporosis Drugs for Women Revenues by Geographical Region 1997-2007
    • Table 7-4: The World Market for Osteoporosis Drugs for Women Share by Geographical Region 1997-2007
    • Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2002 and 2007
    • Table 7-5: Products in Development for Osteoporosis
    • Table 7-6: The World Market for Osteoporosis Drugs for Women Revenues and Market Share by Supplier 2002
    • Figure 7-4: The World Market for Osteoporosis Drugs for Women MarketShare by Leading Supplier 2002
    • Table 8-1: Medications That Can Affect Urination
    • Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revneues by Type 1997-2007
    • Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 1997-2007
    • Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Type 1997-2007
    • Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2002 and 2007
    • Table 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region 1997-2007
    • Table 8-5: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographical Region 1997-2007
    • Figure 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographic Region 2002 and 2007
    • Table 8-6: Products in Development for Urinary Disorders
    • Table 8-7: The World Market for Urinary Bladder Disorder Drugs for Women Revenues and Market Share by Supplier 2002
    • Figure 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Leading Supplier 2002
    • Table 10-1: The Worldwide Market for Women’s Healthcare, Revenues bySegment, 1997-2007
    • Figure 10-1: The Market for Women’s Healthcare Revenues bySegment 1997-2007
    • Table 10-2: The Market for Women’s Healthcare Market Share bySegment 1997-2007
    • Figure 10-2: The Market for Women’s Healthcare Market Share byType 2002 and 2007
    • Table 10-3: The Market for Women’s Healthcare Revenues and Segments of Participation by Leading Market Participants 2002

     

    • Other users found this report page using the following search terms: womens health hrt Hormone replacement therapy Osteoporosis contraception female sexual dysfunction fad fsd womens market health gynecological world 2007 prescription infections size distribution

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.